Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Cisplatin + Dinutuximab beta + Etoposide + Vindesine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
Dinutuximab beta | ch14.18/CHO|APN311|APN-311|APN 311|Qarziba | Dinutuximab beta (ch14.18/CHO) is biosimilar of the anti-GD2 antibody Unituxin (dinutuximab) produced in CHO cells, with a different glycosylation pattern than dinutuximab, which potentially induces antibody-dependent and complement-dependent cytotoxicity against GD2-expressing tumor cells, and reduces liver metastasis (PMID: 30613134, PMID: 15950727). | ||
Etoposide | Vepesid | EPEG|Eposin|VP-16|VP-16-213 | TOPO2 inhibitor 5 | Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary). |
Vindesine | Eldisine |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06485947 | Phase I | Carboplatin + Cisplatin + Cyclophosphamide + Dinutuximab beta + Etoposide + Vincristine Sulfate Cisplatin + Dinutuximab beta + Etoposide + Vindesine Dacarbazine + Dinutuximab beta + Doxorubicin + Ifosfamide + Vincristine Sulfate | Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma (DBPilot) | Not yet recruiting | NLD | 0 |